IMPROVED OXYGENATION OF SYNTHETIC BIO-LIVER DEVICES

改善合成生物肝脏装置的氧合

• 批准号: 6293206
• 负责人: NINA M Lamba-Kohli
• 金额: $ 10万
• 依托单位: COMPACT MEMBRANE SYSTEMS, INC.
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-03-01 至 2002-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6293206
• 关键词: artificial membranes; bioengineering /biomedical engineering; biomedical equipment development; blood oxygenator; cell line; clinical biomedical equipment; fluosol; hemodialysis; liver cells; liver failure; oxygen transport; polypropylenes; surface coating; swine

DESCRIPTION (Verbatim from the Applicant's Abstract): The bioartificial liver has been proposed to perform liver function during hepatic failure unit the native liver has regenerated, or until transplantation is possible. The ideal bioartificial liver would mimic normal liver function. A bioartificial liver could also be used to periodically detoxify those patients with chronic liver diseases. In this hybrid liver system, patients' blood is circulated through a replaceable cartridge interfaced with constantly recirculating viable liver cells, removing toxins from the blood. This proposal will focus on meeting the oxygen demands of the hepatocyte in the recirculating loop. We propose to develop a perfluorinated membrane that will provide bubble less oxygenation, with the required transport characteristics to maintain hepatocyte viability. Additionally, the membrane would offer enhanced resistance to "wet out," and other fouling phenomena associated with conventional hydrophobic membranes, and thus extend the lifetime of liver cells, and reduce the likelihood of introducing pathogenic organisms into the media. Successful completion of the proposed R&D effort will produce and enhanced system that can provide longer-term liver support. PROPOSED COMMERCIAL APPLICATION: Bioartificial livers that provide long term hepatocyte function are expected to provide supportive care and a bridge to transplantation for patients with chronic liver diseases, and improve the prognosis of patients with acute liver failure, avoiding altogether the need for transplantation. A recirculating interfacing device could potentially be used to test the safety of new drugs. Our membrane technology will substantially improve oxygen transfer within the bioartificial liver, and significantly improve its performance.

描述（来自申请人摘要的逐字描述）：生物人工肝 已经提出在肝衰竭单元期间执行肝功能， 自体肝脏已经再生，或者直到移植成为可能。理想 生物人工肝可以模拟正常的肝功能。生物人工肝 也可用于慢性肝病患者的周期性解毒 疾病在这个混合肝脏系统中，患者的血液通过一个 可更换药筒与不断再循环的活肝连接 细胞，清除血液中的毒素。该提案将侧重于满足 再循环回路中肝细胞的氧需求。我们建议 开发一种全氟化膜，它将提供无气泡的氧化， 具有维持肝细胞活力所需的转运特性。 此外，膜将提供增强的抗“浸湿”性， 与常规疏水膜相关的其它结垢现象，和 从而延长肝细胞的寿命，并降低 将病原生物体引入培养基中。成功完成 拟议的研发工作将生产和增强系统，可以提供 长期肝脏支持 拟定商业应用： 提供长期肝细胞功能的生物人工肝有望提供支持性 为慢性肝病患者提供护理和移植的桥梁，并提高 急性肝衰竭患者的预后，完全避免了移植的需要。 再循环接口装置可能用于测试新药的安全性。 我们的膜技术将大幅改善生物人工内的氧气传输 肝脏，并显着提高其性能。